Many postmenopausal women with hormone-dependent breast cancer (requires estrogen and/or progesterone to grow) may be undertreated if they do not receive chemotherapy in addition to hormonal therapy after surgery, according to a Loyola University Health System, Maywood, Ill., study.
Loyola’s Dr. Kathy S. Albain presented the results of a 10-year follow-up of The Breast Cancer Intergroup of North America Trial 0100 at the late breaking session of the San Antonio Breast Cancer Symposium annual meeting here today. "The research shows that, in many cases, tamoxifen or other hormonal therapy alone is not optimal," said principal investigator and first author Albain, professor, division of hematology/oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Ill. "Overall, chemotherapy helped stop the cancer from recurring in postmenopausal women with receptor-positive breast cancer that has spread to the lymph nodes," said Albain. "This survival advantage was greatest when tamoxifen followed chemotherapy, rather than given concurrently.
"Ten-year disease-free-survival estimates were 48 percent for those treated with tamoxifen alone; 53 percent for concurrent chemohormonal therapy; and 60 percent for sequential therapy," said Albain, director, Breast Research Program; co-director of the multidisciplinary Breast Oncology Center; and director of the Thoracic Oncology Program, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Ill.
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences